Altered Platelet Function in Patients on Continuous Infusions of Epoprostenol

Yardumian, D. A.; Machin, Samuel J.

doi:10.1016/s0140-6736(84)91855-5

Cited by 15 publications

(5 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Os exemplos clássicos de lesões vasculares decorrentes do tipo de drogas são: 1) glicose hipertônica (33) ; 2) diclofenaco (34) ; 3) difenil hidantoína (35) ; 4) diazepan (36) ; 5) praxilene (37) ; 6) epoprostenol (38) ; 7) anfotericina B (39) , além das lesões desencadeadas pela velocidade de infusão (40) . Para os cinco fatores de risco relacionados ao cateter intravascular e a sua permanência num mesmo sítio de inserção, obtivemos três fatores de risco com escores e" 0,80 (quadro 2); foi ainda observado o fator de risco Material de composição da agulha do cateter com escore 0,77 e cor do dispositivo com escore < 0,50.…”

Section: Método Método Método Método Métodounclassified

Risco para trauma vascular: proposta do diagnóstico e validação por peritos

Arreguy-Sena

Carvalho

2009

Rev. Bras. Enferm.

View full text Add to dashboard Cite

RESUMO RESUMO RESUMO RESUMO RESUMO Pesquisa de validação conceitual e de conteúdo que objetivou compor o título, os mecanismos de vulnerabilidade e os fatores de risco para o diagnóstico de enfermagem "Risco para Trauma Vascular", segundo a taxonomia da NANDA, bem como validar os elementos desse diagnóstico, a partir da opinião de 60 peritos. Foram identificados 51 fatores relacionados a cinco eixos: medicação e forma/ periodicidade de infusão; cateter intravascular e permanência num mesmo sítio; fixação do cateter intravascular; indivíduo, seus hábitos, padrão comunicacional, estilo de vida e capacidade sensório-motora; e decisões profissionais, política institucional e procedimento. Destes, foram validados 28 fatores de vulnerabilidade (escore e" 0,80). Os resultados evidenciaram "Risco para Trauma Vascular" ser um novo diagnóstico de enfermagem; sugere-se a validação clínica do mesmo. Descritores Descritores Descritores Descritores Descritores: Enfermagem; Processos de enfermagem; Diagnóstico de enfermagem.ABSTRACT ABSTRACT ABSTRACT ABSTRACT ABSTRACT This concept and content validation study aimed to compose the title, vulnerability mechanisms and risk factors for the nursing diagnosis "Risk for Vascular Trauma", according to the taxonomy proposed by NANDA, as well as to validate the elements of this diagnosis, based on 60 experts' opinion. Fifty-one factors were identified, related to five axes: medication and infusion form/periodicity; intravascular catheter and dwelling in the same site; fixation of the intravascular catheter; individuals, their habits, communication standard, lifestyle and sensory-motor ability; and professional decisions, institutional policy and procedures. Among these, 28 vulnerability factors were identified (score e" 0.80). The results evidenced that "Risk for Vascular Trauma" is a new nursing diagnosis, and its clinical validation is suggested. Descriptors: Descriptors: Descriptors: Descriptors: Descriptors: Nursing; Nursing process; Nursing diagnosis. RESUMEN RESUMEN RESUMEN RESUMEN RESUMEN Investigación de validación conceptual y de contenido con objeto de componer el título, los mecanismos de vulnerabilidad y los factores de riesgo para el diagnóstico de enfermería "Riesgo para Trauma Vascular", según la propuesta de la taxonomía de la NANDA, y también validar los elementos de ese diagnóstico, a partir de la opinión de 60 peritos. Fueron identificados 51 factores relacionados a cinco ejes: medicación y forma/periodicidad de infusión; cateter intravascular y permanencia en un mismo sitio; fixación del cateter intravascular; individuo, sus hábitos, patrón comunicacional, estilo de vida y capacidad sensorio-motora; y decisiones profesionales, política institucional y procedimiento. De estos, fueron validados 28 factores de vulnerabilidad (score e" 0,80). Los resultados evidenciaron que "Riesgo para Trauma Vascular" es un nuevo diagnóstico de enfermería; su validación clínica es sugerida. Descriptores Descriptores Descriptores Descriptores Descriptores: Enfermería; Proceso de enferme...

show abstract

Section: Método Método Método Método Métodounclassified

Risco para trauma vascular: proposta do diagnóstico e validação por peritos

Arreguy-Sena

Carvalho

2009

Rev. Bras. Enferm.

View full text Add to dashboard Cite

show abstract

“…This is supported by our results and the fact that one of the reasons for the discordant findings between the COMPERA and REVEAL studies might be the higher use of parenteral prostacyclin analogues in the latter (46% vs 2%, respectively). The lack of effect of warfarin in patients on parenteral prostacyclin analogue therapy could be due to the fact that prostacyclin analogues have antiplatelet effects, decrease plasma levels of tissue plasminogen activator and plasminogen activator inhibitor‐1, and normalize plasma markers of endothelial cell injury …”

Section: Discussionmentioning

confidence: 99%

Impact on survival of warfarin in patients with pulmonary arterial hypertension receiving subcutaneous treprostinil

Ascha

Zhou

Rao

et al. 2017

Cardiovascular Therapeutics

View full text Add to dashboard Cite

Introduction Anticoagulation is a common treatment modality in patients with pulmonary arterial hypertension (PAH). Further studies are needed to appropriately assess the risk / benefit ratio of anticoagulation, particularly in PAH patients receiving PAH-specific therapies. Aims We use observational long-term data on PAH patients treated with subcutaneous (SQ) treprostinil from a large open-label study. Patients were followed for up to four years. The use of warfarin and bleeding events were recorded. Results At total of 860 patients (age [mean ± SD] 46 ± 15 years, 76% female, 83% Caucasian, 49% idiopathic PAH, and 76% NYHA functional class III) were included. All patients received SQ treprostinil (15% also other PH-therapies) and 590 (69%) received warfarin during the study. The proportions of women, African-American and IPAH patients were higher in the group receiving warfarin. A higher proportion of patients with congenital heart disease and porto-pulmonary hypertension did not receive warfarin. There were no differences in unadjusted long-term survival between PAH patients receiving warfarin or not (log-rank test, p value=0.69), even when only considering idiopathic PAH (p=0.32). In addition, no difference was found in adjusted long-term survival both in PAH (p=0.84) and idiopathic PAH patients (p=0.44) based on the use of warfarin. Furthermore, no survival difference based on the use of warfarin were noted between propensity score matched PAH patients (p=0.37). Conclusions Long-term anticoagulation with warfarin was not associated with any significant effect on survival in PAH or idiopathic PAH patients treated with SQ treprostinil.

show abstract

“…This contrasts with the medications reported in COMPERA, where far fewer patients were reported to be on prostacyclin analogues. Prostacyclin therapy not only provides vasodilation in PAH, but has also been shown to alter hemostatic and platelet pathways, possible decreasing the in situ thrombosis and hypercoagulability observed in patients with PAH (3,7,(30)(31)(32). Of note, bleeding risks are increased in patients with iPAH, CTD-PAH and chronic thromboembolic pulmonary hypertension when vitamin K antagonists (VKA) were used in conjunction with prostacyclin (33).…”

Section: Perspectivementioning

confidence: 99%

Where do we go from here? Reappraising the data on anticoagulation in pulmonary arterial hypertension

Cirulis

Ryan

2016

J. Thorac. Dis.

View full text Add to dashboard Cite

The use of anticoagulation as part of the treatment regimen in pulmonary arterial hypertension (PAH) remains a topic of debate. A recently published analysis of anticoagulation use in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) study offers conflicting conclusions regarding the benefit of this therapeutic strategy. There remains no robust randomized trial in PAH weighing the risks versus benefits of including anticoagulation in treatment regimens, leaving clinicians to surmise value in individual patients. Reexamination of available data may help to provide guidance on this controversial topic in the absence of future dedicated investigations.

show abstract

Altered Platelet Function in Patients on Continuous Infusions of Epoprostenol

Cited by 15 publications

References 2 publications

Risco para trauma vascular: proposta do diagnóstico e validação por peritos

Risco para trauma vascular: proposta do diagnóstico e validação por peritos

Impact on survival of warfarin in patients with pulmonary arterial hypertension receiving subcutaneous treprostinil

Where do we go from here? Reappraising the data on anticoagulation in pulmonary arterial hypertension

Contact Info

Product

Resources

About